The June 2026 Total Pharmacy Solutions Summit, hosted by Drug Topics, wrapped this week as one of the most operationally dense roadmaps for pharmacy business leaders to emerge from any conference this year. Four critical intelligence streams came out of this summit. Here is each one, along with the specific action it demands.
Signal 1: CMR Policy Changes Are a Revenue Opportunity, If You Have the Workflow to Capture It
Kevin Boesen, PharmD, MBA, chief commercial officer at Outcomes, presented a session titled “From Payer Change to Pharmacy Opportunity: Turning CMR Policy Shifts into Revenue and Efficiency.” Boesen broke down how recent policy changes are reshaping the role of comprehensive medication reviews and how innovation and automation, including workflow intelligence and tools like PillCount, can help pharmacies reduce burden and turn increased demand into scalable revenue.
The session’s central argument: CMR demand is rising as payer policy changes move more patients into eligible populations, but the pharmacies capturing that revenue are the ones that have reduced their per-review documentation burden enough to handle volume.
Stephanie Downing, MBA, senior product manager at Outcomes, reinforced this point in a separate presentation, noting that “over the past decade, we’ve seen a fundamental shift in the role of pharmacists. Traditionally, pharmacies focused mainly on dispensing medications. However, with the rise of value-based care, pharmacies are increasingly recognized as crucial players in patient health management.” Outcomes integrate with existing pharmacy management systems, providing a unified platform for clinical services, electronic health records, and patient engagement, supporting comprehensive medical billing capabilities, revenue cycle management, and advanced reporting.
The bottleneck is not CMR eligibility. It is throughput. A pharmacist who spends 45 minutes on documentation per review completes far fewer than one who can execute the same clinical process in 20 minutes with automation support. The pharmacies that solve the documentation burden problem now will scale CMR revenue as policy continues to expand eligibility. The ones that don’t will watch that revenue accrue to competitors with faster workflows.
Signal 2: The Keynote Named Fragmented Reimbursement as the Top Blocker and Outlined a Structural Solution
The summit keynote highlighted fragmented reimbursement and operational complexity as the primary blockers to clinical service adoption, proposing regionally driven models to scale pharmacist-delivered care sustainably.
“Regionally driven models” is the key phrase. The pharmacies and pharmacy networks solving the reimbursement fragmentation problem are not doing it by waiting for national payer policy to align. They are building regional collaborative practice agreements, regional payer relationships, and regional value-based care contracts that allow pharmacist-delivered services to flow through established billing channels at the local level.
This aligns directly with the advocacy signal from the NCPA Congressional Fly-In covered earlier in this newsletter: the real action on pharmacist provider status and reimbursement is at the state level, not the federal level. Every pharmacist who attends a state legislative session, builds a relationship with a regional Medicaid managed care plan, or joins a regional accountable care organization is executing the regionally driven model the summit keynote described.
The near-term move: identify the two or three largest payers in your market. Find out what clinical pharmacy services they currently reimburse and what their Stars or HEDIS performance priorities are for 2027 contract cycles. That conversation, initiated before open enrollment and contracting season, positions your pharmacy for inclusion in performance-based payment models that didn’t exist five years ago.
Signal 3: The GLP-1 Compounding Window Is Closing, Know Your Legal Position Before the Comment Deadline
This is the most time-sensitive signal from the summit, and it requires immediate attention from any pharmacy operating in the compounding or GLP-1 adjacent space.
The FDA proposed permanently closing both the 503B bulk compounding pathway and, effectively, the 503A patient-specific pathway for semaglutide, tirzepatide, and liraglutide. The proposed rule would exclude these GLP-1s from the 503B bulks list, citing no clinical need for outsourcing facilities to compound these agents from bulk API. The shortage-list pathway that had permitted large-scale compounding was eliminated when the FDA declared shortages resolved, with 503A enforcement deadlines passing in April and May 2025 and 503B deadlines passing shortly after. Legal challenges by the Outsourcing Facilities Association failed to secure preliminary injunctions.
The public comment period on the April 30, 2026 proposed rule closes June 29, 2026. Industry analysts expect the ban to be finalized by Q3 2026, effectively ending the era of mass-scale GLP-1 compounding. 503B outsourcing facilities would be prohibited from compounding these agents under any circumstances, regardless of future market conditions. 503A pharmacies operating under patient-specific prescriptions technically face a different statutory framework, but the “essentially a copy” prohibition applies when the shortage designation no longer exists, making regular or inordinate amounts of patient-specific compounding of these agents legally precarious.
Adverse-event reports associated with compounded GLP-1 products include more than 455 semaglutide reports and more than 320 tirzepatide reports, with dosing errors from multidose vials and counterfeit supply cited as contributing safety concerns. Pharmacists should steer patients currently using compounded GLP-1s toward savings programs, branded manufacturer assistance options, and the cash-pay access pathways covered in a prior issue of this newsletter.
The summit’s legal session with Dae Lee, PharmD, Esq, and Lucas Morgan, Esq, of Buchanan, Ingersoll and Rooney covered specific risk-mitigation strategies. Their session, “Compounding, Peptides, and GLP-1s: Opportunities and Risks for Pharmacists,” reviewed FDA and state board enforcement trends around compounding, peptides, and GLP-1-related demand, recommending specific risk-mitigation strategies to avoid regulatory exposure as the FDA continues to scrutinize 503A and 503B operators.
If your pharmacy currently has patients on compounded GLP-1 products, whether dispensed by your pharmacy or by another compounder, this week’s action is to review your transition protocol: how will you move these patients to commercially available branded options, to the GoodRx cash-pay pathway at $149 to $299 per month covered in a prior issue, or to manufacturer savings programs before finalization of the rule?
Signal 4: The Advanced Pharmacy Technician Is Your Most Underutilized Operational Lever
Mike Johnston, CPhT-Adv, founder and CEO of the National Pharmacy Technician Association, presented data on recruiting and upskilling pharmacy technicians into advanced roles to improve workflow efficiency, reduce pharmacist burnout, and expand patient care services, positioning the advanced-certified pharmacy technician as the operational lever that frees the pharmacist for billable clinical work.
This is the operational insight that most pharmacy business owners haven’t fully acted on yet. The math is straightforward: if a pharmacist earns $65 to $80 per hour and spends three hours a day on tasks that an advanced-certified technician could handle, every day contains $200 or more in misallocated labor. Redirect those three hours toward billable CMR encounters, pharmacogenomics consultations, or GLP-1 coaching visits, and the ROI on the advanced technician investment is measured in weeks, not years.
The CPhT-Adv credential indicates deep, specialized knowledge across several critical areas of pharmacy practice, going well beyond the entry-level CPhT. Unlike the basic certification, which verifies foundational knowledge, the CPhT-Adv recognizes mastery in areas including point-of-care testing, regulatory compliance, sterile and nonsterile compounding, and supply chain management.
PTCB awards the CPhT-Adv to candidates who hold an active CPhT and have completed at least three years of work experience plus four PTCB assessment-based certificate programs or three certificate programs plus the CSPT certification. There is no additional exam and no application fee through PTCB.
BPTS, the credentialing body established by NPTA, offers its own CPhT-Adv pathway accessible to technicians certified through either NHA or PTCB, with renewal every two years and a $29 renewal fee. The credential is designed to be accessible and affordable specifically to democratize advanced certification across all certified technicians.
The ASHP PAI 2030 recommendations covered in the previous issue explicitly support this trajectory: pharmacy technicians should have complete responsibility for advanced technical and supporting activities, and individually credentialed advanced technicians are specifically called out as an operational model that expands pharmacist capacity for clinical work.
The summit’s workforce session framed this as a two-sided investment: upskilling the technician who is already on your team is faster, cheaper, and more culturally aligned than hiring new clinical staff. And the pharmacist who gains back three hours of clinical capacity per day can generate significantly more billable clinical encounters in a single quarter than the cost of the technician’s advanced certification pathway.
The Two Bonus Signals Worth Noting
Beyond the four major tracks, two additional summit sessions mapped concrete clinical billing infrastructure that pharmacists can build on immediately.
Influenza vaccination strategy: The evidence-based influenza vaccination session covered structured seasonal vaccine clinic models with CPT billing infrastructure already in place. The pharmacies that build standing flu clinic protocols, community outreach partnerships, and employer on-site vaccination programs during the summer will generate measurable Q4 revenue. The infrastructure exists. The question is whether it is built proactively or reactively.
Atrial fibrillation anticoagulation: The guideline-directed AF anticoagulation session covered emerging Factor XI/XIa inhibitors entering the pipeline alongside existing DOAC management. This is a high-complexity, high-adherence-sensitivity drug class where pharmacist clinical expertise directly reduces bleeding events, stroke risk, and emergency department utilization. The CPT codes for anticoagulation management services, particularly for pharmacist-managed anticoagulation clinics under collaborative practice agreements, exist and are billable. Building a structured AF anticoagulation management service now positions your pharmacy for a drug class that will expand significantly as Factor XIa inhibitors receive FDA approvals in the next two to three years.
The DSCSA Deadline Hidden Inside the Summit Agenda
NABP presenters outlined dispenser Drug Supply Chain Security Act readiness, emphasizing authorized trading partner verification and transaction data workflows as the small dispenser exemption expires.
This is a compliance signal that too many independent pharmacies are still deferring. The small dispenser exemption that has allowed smaller pharmacies to delay full DSCSA compliance is ending. Authorized trading partner verification, interoperable electronic tracking, and transaction data workflows are not optional after the exemption expires. Pharmacies that have not yet begun this process need to contact their wholesaler and pharmacy management system vendor this week for a specific implementation timeline.
Your Action This Week
Four concrete moves, one from each major signal:
CMR throughput: Audit your current CMR documentation workflow. Time one complete review from initiation to billing submission. Then identify one step that automation tools like Outcomes’ PillCount could compress. Reducing average review time by 15 minutes per encounter is worth significant annualized revenue if your current volume is 10 or more reviews per month.
Regionally driven reimbursement: Contact your state pharmacy association and ask for a list of regional payers who currently have value-based care contracts that include community pharmacy. Then request a meeting with the pharmacy network manager at the largest Medicaid managed care plan in your market.
GLP-1 compounding transition: Review your patient panel for any patients currently on compounded GLP-1 products. Build a transition protocol before the June 29 comment deadline, not after the final rule lands.
Advanced tech investment: Identify the one technician on your team who is closest to CPhT-Adv eligibility. Calculate what their advanced certification enables you to delegate. Then calculate the clinical billing value of the pharmacist hours you would recapture. If the math is positive, which it almost certainly is, begin the certification pathway conversation this week.
The next 12 months of pharmacy revenue opportunity have been mapped. The pharmacies that act on these signals now will be the ones leading their markets when the year ends.
Sources: Drug Topics (Register Today: June 2026 Total Pharmacy Solutions Summit, Full Agenda and Session Descriptions), Drug Topics (Pharmacy Industry Transitions From Traditional Dispensing to Clinical Services, June 2026), Pharmacy Times (FDA Moves to Permanently Close the Door on Compounded GLP-1s, May 2026), Medical News Today (FDA Moves to Remove GLP-1 Medications from 503B Bulks List, May 2026), Orrick (FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs, May 2026), LotiLabs (Compounded Semaglutide/Tirzepatide Legal Status 2026, May 2026), PTCB (Advanced Certified Pharmacy Technician CPhT-Adv Credential Overview), BPTS / NPTA (CPhT-Adv Advanced Certification Pathway and Renewal Requirements), Pharmacy Times (Navigating the Certification Journey: Why Credentialing Matters for Pharmacy Technicians, April 2026)